IQVIA Holdings Inc. (NYSE:IQV) Stake Decreased by M&T Bank Corp

M&T Bank Corp decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 120,977 shares of the medical research company's stock after selling 8,354 shares during the period. M&T Bank Corp owned about 0.07% of IQVIA worth $27,992,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Lazard Asset Management LLC boosted its position in IQVIA by 2.9% during the third quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company's stock worth $568,460,000 after purchasing an additional 80,189 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in IQVIA by 3.4% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company's stock worth $457,483,000 after acquiring an additional 77,422 shares in the last quarter. Wellington Management Group LLP raised its position in IQVIA by 1.0% during the third quarter. Wellington Management Group LLP now owns 1,816,266 shares of the medical research company's stock worth $357,350,000 after acquiring an additional 17,139 shares during the period. JPMorgan Chase & Co. lifted its holdings in IQVIA by 8.7% during the third quarter. JPMorgan Chase & Co. now owns 1,781,283 shares of the medical research company's stock valued at $350,467,000 after purchasing an additional 142,707 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of IQVIA by 1.8% in the third quarter. Northern Trust Corp now owns 1,737,315 shares of the medical research company's stock valued at $341,817,000 after purchasing an additional 31,413 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research reports. Robert W. Baird decreased their price target on shares of IQVIA from $254.00 to $245.00 and set a "neutral" rating on the stock in a research note on Friday. SVB Leerink started coverage on IQVIA in a research note on Monday, February 26th. They issued an "outperform" rating and a $290.00 price target on the stock. Leerink Partnrs reissued an "outperform" rating on shares of IQVIA in a research note on Monday, February 26th. Evercore ISI lowered their target price on shares of IQVIA from $275.00 to $250.00 and set an "outperform" rating on the stock in a research note on Friday. Finally, StockNews.com upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $257.57.

IQVIA Trading Up 0.6 %

Shares of IQV stock traded up $1.23 during trading on Friday, hitting $223.37. 1,052,929 shares of the stock traded hands, compared to its average volume of 831,136. The firm has a market capitalization of $40.54 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 2.15 and a beta of 1.52. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.86. The firm's fifty day moving average price is $244.08 and its 200-day moving average price is $224.01.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to analysts' expectations of $3.80 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The company's revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.54 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Kevin C. Knightly sold 8,607 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the business's stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company's stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,285 shares of company stock valued at $10,331,003. Company insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.